Managing the Risks of ADHD Treatments

Current Psychiatry Reports

Volumn 16, Issue 10, 2014, Pages

  Schneider, Benjamin N ^a   Enenbach, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADHD; Alpha agonists; Appetite; Atomoxetine; Cardiovascular; Growth; Mania; Pharmacotherapy; Priapism; Psychosis; Seizure; Side effects; Sleep; Stimulants; Substance use disorders; Tics

Indexed keywords

EID: 84905881238     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0479-3     Document Type: Review

References (61)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.
2. Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99. A notable review in that it focused on long-term outcomes in which ADHD treatments were shown to reduce the negative impact of ADHD.
3. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry. 1999;56:1073–86.
4. Döpfner M, Ise E, Wolff Metternich-Kaizman T, Schürmann S, Rademacher C, Breuer D. Adaptive multimodal treatment for children with attention-deficit/hyperactivity disorder: an 18 month follow-up. Child Psychiatry Hum. Dev. 2014. An 18-month follow-up to the Cologne Adaptive Multimodal Treatment (CAMT) study showing that the initial advantage of combined treatment over behavioral treatment was no longer evident at 18 months.
5. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.
6. Partridge B, Lucke J, Hall W. Over-diagnosed and over-treated: a survey of Australian public attitudes towards the acceptability of drug treatment for depression and ADHD. BMC Psychiatry. 2014;14:74.
7. Findling RL, Biederman J, Wilens TE, Spencer TJ, McGough JJ, Lopez FA, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147:348–54.
8. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011;50:978–90. Showed a small subset of children and adolescents may have a greater increase in pulse or blood pressure. Found it to be extremely rare for a child or adolescent to have a serious cardiovascular event during treatment with the risk being similar to that in people not receiving treatment.
9. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev. 2002;22:1107–31.
10. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21:92–5.
11. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008;47:189–98.
12. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85.e2. A notable paper in that it looks at the safety of combining psychostimulants and alpha-2-agonists for the treatment of ADHD. Combination treatment was shown to be effective, and no new safety concerns were presented.
13. Roesch B, Corcoran M, Haffey M, Stevenson A, Wang P, Purkayastha J, et al. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D. 2013;13:53–61. Open-label study of adults comparin Intuniv, Concerta, or combination treatment. No significant drug-drug interactions were found.
14. Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:147–56. Cohort analysis showing cardiovascular events were rare and not associated with stimulant use, suggesting the safety of ADHD medication treatment in young people without known risk factors.
15. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:2673–83.
16. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896–904. Large cohort study showing no evidence that current use of ADHD drugs was associated with increased risk of cardiovascular events.
17. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127:1102–10. Cohort study that looked at stimulants as well as atomoxetine showing the rate of cardiovascular events to be very low and not significantly higher than in control subjects.
18. Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ. 2012;345:e4627.
19. Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: A nationwide prospective cohort study. J. Child Adolesc. Psychopharmacol. 2014. Cohort study that looked at long-term effects of stimulants. Notable for the longer observation period.
20. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J. Dev. Behav. Pediatr. 2008;29:335.
21. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122:451–3.
22. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Cardiac Congenital Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117:2407–23.
23. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54:227–46. A notable review on medication management of ADHD. Provides expert consensus of the members of the European ADHD Guidelines Group.
24. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475–88.
25. Cheng JYW, Chen RYL, Ko JSN, Ng EML. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacol (Berl). 2007;194:197–209.
26. Wang Y, Zheng Y, Du Y, Song DH, Shin Y-J, Cho SC, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007;41:222–30.
27. Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr. 2010;157:635–40. 640.e1.
28. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:994–1009.
29. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;14:65–73.
30. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:E105.
31. Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med. 2010;11:652–8.
32. Tjon Pian Gi CV, Broeren JPA, Starreveld JS, Versteegh FGA. Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study. Eur J Pediatr. 2003;162:554–5.
33. James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752–5.
34. Cortese S, Konofal E, Lecendreux M, Arnulf I, Mouren M-C, Darra F, et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep. 2005;28:1007–13.
35. Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am. 2011;58:99–120. xi.
36. Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol. 2006;48:616–21.
37. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48:884–93.
38. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50:9–21.
39. Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31:328–41.
40. Molina BSG, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52:250–63. Notable follow-up to the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder looking at the relationship between medication and subsequent substance use disorder. Medication for ADHD did not impact future substance use or substance use disorders.
41. APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
42. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179–85.
43. Groenman AP, Oosterlaan J, Rommelse NNJ, Franke B, Greven CU, Hoekstra PJ, et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry. 2013;203:112–9. Study in which stimulant use, especially at an earlier age, seemed to reduce the risk of future substance use disorders.
44. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21–31.
45. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;100:96–106.
46. Lakić A. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. Vojnosanit Pregl. 2012;69:201–4.
47. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am. 1992;15:191–222.
48. Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry Elsevier. 1988;27:336–41.
49. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1294–303.
50. Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, et al. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial. J Atten Disord. 2014;18:123–32. A notable outpatient clinical trial that found lisdexamfetamine dimesylate improved both ADHD symptoms and emotional lability.
51. Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123:611–6.
52. Goldsmith M, Singh M, Chang K. Antidepressants and psychostimulants in pediatric populations: is there an association with mania? Paediatr Drugs. 2011;13:225–43.
53. Davis SM, Katusic SK, Barbaresi WJ, Killian J, Weaver AL, Ottman R, et al. Epilepsy in children with attention-deficit/hyperactivity disorder. Pediatr Neurol. 2010;42:325–30.
54. Fosi T, Lax-Pericall MT, Scott RC, Neville BG, Aylett SE. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Epilepsia. 2013;54:2071–81.
55. Santos K, Palmini A, Radziuk AL, Rotert R, Bastos F, Booij L, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol. 2013;55:654–60. Pilot study evaluating safety and efficacy of methylphenidate in a population with difficult-to-treat epilepsy.
56. Kelly BD, Lundon DJ, McGuinness D, Brady CM. Methylphenidate-induced erections in a prepubertal child. J Pediatr Urol. 2013;9:e1–2.
57. Cakin-Memik N, Yildiz O, Sişmanlar SG, Karakaya I, Ağaoğlu B. Priapism associated with methylphenidate: a case report. Turk J Pediatr. 2012;52:430–4.
58. Husár M, Zerhau P. Priapism in childhood—case report of 14-year-old boy. Rozhl Chir. 2006;85:329–30.
59. Schwartz RH, Rushton HG. Stuttering priapism associated with withdrawal from sustained-release methylphenidate. J Pediatr. 2004;144:675–6.
60. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol. 2014;28:204–11.
61. Agosti V, Chen Y, Levin FR. Does attention deficit hyperactivity disorder increase the risk of suicide attempts? J Affect Disord. 2011;133:595–9.